Tirzepatide

GLP-2 (TZ) is a 39-amino-acid synthetic peptide engineered to act as a single-molecule agonist at two incretin receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Its backbone is built on a GIP-derived sequence carrying substitutions that confer activity at both receptors, plus a fatty-acid chain that promotes albumin binding and extends circulation time.

The peptide ships as a lyophilised powder in a sealed glass vial across 10 mg, 20 mg and 50 mg presentations. Each lot carries a Certificate of Analysis recording identity and purity. Supplied strictly as a laboratory reference material for research use, and not for human or veterinary use.

Dual incretin receptor agonists are among the most heavily studied structures in current peptide pharmacology. Questions examined in the published literature include:

• Relative potency and signalling bias at GIPR versus GLP-1R, and how substitution patterns shift that balance
• Recruitment of G-protein versus beta-arrestin pathways and the resulting receptor internalisation profiles
• cAMP signalling kinetics in receptor-transfected cell lines
• How albumin-binding acylation changes half-life and exposure in preclinical species
• Structural work resolving how one ligand accommodates two distinct receptor binding pockets

Each item describes an area of ongoing scientific investigation. No claim is made about any effect in humans, and this material is sold for in vitro and preclinical laboratory use only.